Addex Therapeutics Ltd (ADXN)

1.3600 +0.0600 (+4.62%) At close: 03:59PM EST

Addex Therapeutics Ltd

Chemin des Mines, 9
Geneva 1202
Switzerland
41 22 884 1555
https://www.addextherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 26

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Timothy Mark Dyer	Co-Founder, CEO & Director	N/A	N/A	1968
Dr. Roger G. Mills M.D.	Chief Medical Officer & Director	N/A	N/A	1957
Mr. Lénaic Teyssédou	Head of Fin.	N/A	N/A	1986
Dr. Jean-Philippe Rocher Ph.D.	Head of Discovery - Chemistry	N/A	N/A	1959
Dr. Robert Lutjens	Head of Discovery - Biology	N/A	N/A	1968
Dr. Mikhail Kalinichev Ph.D.	Head of Translational Science	N/A	N/A	1968
Dr. Werner Henrichi Ph.D.	Consultant	N/A	N/A	1943

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Corporate Governance

Addex Therapeutics Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.